Therapy Areas: Inflammatory Diseases
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
13 November 2026 - Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company that develops, manufactures, and commercialises medicines for the treatment of oncology, autoimmune, ...
Jubilant Therapeutics to present LSD1 and HDAC6 (CoREST) orally administered dual inhibitor Phase 1/2 study results at 68th ASH Annual Meeting
11 November 2026 - Jubilant Therapeutics Inc, a US-based, clinical-stage biopharmaceutical company that is advancing precision therapeutics for myeloproliferative neoplasms (MPNs), announced on Tuesda...
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
9 November 2026 - Biopharmaceutical company Janux Therapeutics Inc (Nasdaq: JANX) on Monday reported positive initial Phase 1 results for JANX011 in healthy volunteers, supporting plans to advance the...
Bio-Thera's golimumab biosimilar receives Chinese regulatory approval
9 November 2026 - Commercial-stage biopharmaceutical company Bio-Thera Solutions Ltd (SHA:688177) announced on Monday that China's National Medical Products Administration (NMPA) has approved its...
Chinese regulator accepts Lynk Pharmaceuticals' New Drug Application for zemprocitinib in RA treatment
6 November 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, announced on Thursday that the New Drug Application (NDA) for i...
ABIONYX Pharma partners with Lille University Hospital to explore CER-001 for severe burn patients
4 November 2026 - ABIONYX Pharma (Euronext Paris:ABNX), a biopharma company focused on breakthrough biotherapies to address life-threatening conditions with no effective treatments, announced on Wedne...